Most development-stage biopharmaceutical companies pin their hopes on a single clinical hypothesis evaluated with a handful of drug candidates at best. Fate Therapeutics (NASDAQ:FATE) is not most early stage companies.
The cellular therapy pioneer is develop⦠[+8747 chars]Source
